EUVIMEDEUVIMED entdecken
Crossref

Acute myocardial infarction in patients with cancer: outcomes and P2Y12 inhibition

Andres Cordova Sanchez, Chris E Holmes, Harold L Dauerman, Tanush Gupta

Journal of Thrombosis and Thrombolysis · 2025

DOI: 10.1007/s11239-025-03092-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Thrombosis and Thrombolysis, 2025. Verfasst von Andres Cordova Sanchez und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, University of Vermont Medical Center, Burlington, VT, USA. Hauptthemen laut MEDLINE: Purinergic P2Y Receptor Antagonists, Myocardial Infarction, Neoplasms, Percutaneous Coronary Intervention. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer patients are at an elevated risk of bleeding and ischemic events. There are limited comparative real-world data on outcomes of all-comer cancer patients after percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) compared with non-cancer patients. There are also limited comparative data to guide P2Y12 inhibitor choice in cancer patients undergoing PCI. We queried the TriNetX research database from 2015 to 2023 to identify adult patients who received PCI for AMI. AMI patients were then stratified into cancer and non-cancer patients. Propensity score matching was used to account for imbalances in baseline characteristics. Cancer patients were further categorized into those who received dual antiplatelet therapy (DAPT) with ticagrelor or clopidogrel in addition to aspirin. Outcomes of interest included all-cause mortality and major bleeding at 30-days and 1-year. Of 139,342 patients who underwent PCI for AMI, 6,766 (4.9%) had a history of cancer. Compared with AMI patients without cancer, cancer patients had higher 1-year all-cause mortality (20.1% vs. 12.7%; HR 1.59; 95% CI, 1.46-1.73) and major bleeding (16.9% vs. 10.2%; HR 1.69; 95% CI 1.54-1.86). Among cancer patients with AMI, those treated with ticagrelor-based DAPT after PCI had similar incidence of bleeding complications compared with those treated with clopidogrel (HR 1.04; 95% CI 0.77-1.40). Cancer is an adverse prognostic marker for AMI outcomes and is independently associated with substantially higher mortality and bleeding risk. Among cancer patients undergoing PCI for AMI, ticagrelor use is associated with similar bleeding events compared with clopidogrel.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Purinergic P2Y Receptor AntagonistsMyocardial InfarctionNeoplasmsPercutaneous Coronary InterventionHumansFemaleMaleAgedMiddle AgedTicagrelorClopidogrelHemorrhagePlatelet Aggregation InhibitorsTreatment OutcomeAspirinRetrospective Studies

Stichwörter der Autor:innen

CancerCardio-oncologyDual antiplatelet therapyHigh bleeding riskMyocardial infarction

Substanzen

Purinergic P2Y Receptor AntagonistsTicagrelorClopidogrelPlatelet Aggregation InhibitorsAspirin

Autor:innen und Institutionen

  • Division of Cardiology, University of Vermont Medical Center, Burlington, VT, USA.
  • Division of Hematology and Oncology, University of Vermont Medical Center, Burlington, VT, USA.
  • Division of Cardiology, University of Vermont Medical Center, Burlington, VT, USA. Tanush.Gupta@UVMHealth.Org.

Zitieren

APA

Cordova Sanchez, A., Holmes, C. E., Dauerman, H. L., & Gupta, T. (2025). Acute myocardial infarction in patients with cancer: outcomes and P2Y12 inhibition. Journal of Thrombosis and Thrombolysis. https://doi.org/10.1007/s11239-025-03092-4

Vancouver

Cordova Sanchez A, Holmes CE, Dauerman HL, Gupta T. Acute myocardial infarction in patients with cancer: outcomes and P2Y12 inhibition. Journal of Thrombosis and Thrombolysis. 2025. doi:10.1007/s11239-025-03092-4

BibTeX
@article{CordovaSanchez2025,
  author = {Cordova Sanchez, Andres and Holmes, Chris E and Dauerman, Harold L and Gupta, Tanush},
  title = {Acute myocardial infarction in patients with cancer: outcomes and P2Y12 inhibition},
  journal = {Journal of Thrombosis and Thrombolysis},
  year = {2025},
  doi = {10.1007/s11239-025-03092-4}
}
Kostenlos starten →